Modulation of cellular behavior by exogenous messenger RNA

Leukemia

Volumn 20, Issue 5, 2006, Pages 767-769

  Ponsaerts, P ^a,b   Berneman, Zwi N ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GREEN FLUORESCENT PROTEIN; LIPOSOME; MESSENGER RNA; PLASMID DNA; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; VIRUS ANTIGEN; VIRUS VECTOR;

APOPTOSIS; CELL ACTIVITY; CELL BASED GENE THERAPY; CELL COMMUNICATION; DENDRITIC CELL; DNA VECTOR; DRUG FORMULATION; EDITORIAL; ELECTROPORATION; FLOW CYTOMETRY; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC CODE; GENETIC ENGINEERING; GENETIC STABILITY; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE SUBPOPULATION; MACROMOLECULE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMODESMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL GENE THERAPY; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

EID: 33646157981     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404219     Document Type: Editorial

References (24)

1. Van Tendeloo VFI, Van Broeckhoven C, Berneman ZN. Gene therapy: principles and applications to hematopoietic cells. Leukemia 2001; 15: 523-544.
2. Gonin P, Buchholz CJ, Pallardy M, Mezzina M. Gene therapy biosafety: scientific and regulatory issues. Gene Therapy 2005; 12: S146-S152.
3. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: Genetic modification of dendritic cells. J Gene Med 2004; 6: 1175-1188.
4. Menendez P, Wang L, Bhatia M. Genetic manipulation of human embryonic stem cells: A system to study early human development and potential therapeutic applications. Curr Gene Ther 2005; 5: 375-385.
5. Zehavi-Willner T, Lane C. Subcellular compartmentation of albumin and globin made in oocytes under the direction of injected messenger RNA. Cell 1977; 11: 683-693.
6. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465-472.
7. Nair SK, Boczkowski D, Morse M, Cumming RI, Lyerly HK, Gilboa E. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998; 16: 364-369.
8. Van Tendeloo VF, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: Superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001; 98: 49-56.
9. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA-based electrotransfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002; 259: 191-203.
10. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 2003; 101: 977-982.
11. Van Gulck ERA, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood 2006; 107: 1818-1827.
12. + T cells by dendritic cells transfected with mRNA encoding cytoplasmor lysosome-targeted Nef. Blood 2006; 107: 1963-1969.
13. Van Driessche A, Gao L, Stauss HJ, Ponsaerts P, Van Bockstaele DR, Berneman ZN et al. Antigen-specific cellular immunotherapy of leukemia. Leukemia 2005; 19: 1863-1871.
14. Schaft N, Dorrie J, Muller I, Beck V, Baumann S, Schunder T et al. A new way to generate cytolytic tumor-specific T cells: Electroporation of RNA coding for a T cell receptor into T lymphocytes. Cancer Immunol Immunother 2006; doi: 10.1007/s00262-005-0098-2.
15. Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VF, Berneman ZN. Messenger RNA electroporation: An efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol 2005; 43: 213-216.
16. Smits E, Ponsaerts P, Lenjou M, Nijs G, Van Bockstaele DR, Berneman ZN et al. RNA-based gene transfer for adult stem cells and T cells. Leukemia 2004; 18: 1898-1902.
17. Yoo BC, Kragler F, Varkonyi-Gasic E, Haywood V, Archer-Evans S, Lee YM et al. A systemic small RNA signaling system in plants. Plant Cell 2004; 16: 1979-2000.
18. Lucas WJ, Lee JY. Plasmodesmata as a supracellular control network in plants. Nat Rev Mol Cell Biol 2004; 5: 712-726.
19. Haywood V, Yu TS, Huang NC, Lucas WJ. Phloem long-distance trafficking of gibberellic acid-insensitive RNA regulates leaf development. Plant J 2005; 42: 49-68.
20. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94: 3791-3799.
21. Baj-Krzyworzeka M, Majka M, Pratico D, Ratajczak J, Vilaire G, Kijowski J et al. Platelet-derived microparticles stimulate proliferation, survival, adhesion, and chemotaxis of hematopoietic cells. Exp Hematol 2002; 30: 450-459.
22. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, Baran J, Urbanowicz B, Branski P et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006; DOI: 10.1007/ s00262-005-0075-9.
23. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: Evidence for horizontal transfer of mRNA and protein delivery. Leukemia 2006; 20: 847-856.
24. Hess PR, Boczkowski D, Nair SK, Snyder D, Gilboa E. Vaccination with mRNAs encoding tumor-associated antigens and granulocytemacrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2005; 20: 1-12.